Free up your time to focus on what’s important. We’ll take care of the U.S. biosimilar market monitoring, analysis and insights.

The All Things Biosimilar information platform is comprised of various offerings that, in the aggregate, provide a full picture of the U.S. biosimilars market. User-built by someone who has worked in biosimilars for over 15 years, the platform is designed to provide solutions to complex questions in a simple way. With different subscription options, clients have the flexibility to invest for the right level of information at the right price.

Subscription Types

All Things Biosimilars Basic

Basic Subscription to ATB includes the following:

All Things Biosimilars Premium

Premium Subscription to ATB includes the following:

All Things Biosimilar provides U.S. biosimilar market monitoring, insights and analysis across a set of offerings including:

  • The 351(k) Report

    The Flagship Analysis, The 351k Report, which aggregates key news stories, analysis and insights from around the biosimilar market and inclusive of the All Things Biosimilar opinion and perspective. Delivered almost every week, this report will keep you up to speed on the market with the lens of an experienced industry professional helping you focus on what’s most important.

  • The LUPINE Data Set

    Our version of the “Purple Book”- but with so much more. This excel-based resource provides a comprehensive list of Who is Doing What, along with CMS pricing and other competitive metrics. We keep this updated on a weekly basis to make sure clients are always up to date on their intelligence.

  • Biosimilar Calendar

    In order to stay up to date with the ever-changing market, we have put together an excel-based list of key conferences, PDUFA dates, market and company catalyst, as well as TA-specific social media considerations related to the biosimilar market. Again- we update this weekly to keep you informed.

  • Product Reports

    Available to our Premium prescribers, the All Things Biosimilar Product reports will feature an incredible amount of information ranging from a proprietary competitive ranking of assets to reviews of marketing materials with tons of analysis in between. The 2025 products included in the product report include adalimumab, ustekinumab, denosumab, tocilizumab and omalizumab. Enjoy!

  • Earnings Reports

    Available to our Premium prescribers are quarterly earnings reviews and wrap ups which will include post earnings call insights and then supplemental perspectives from equity analysts. Companies included in the report will be based on client needs and include companies in pharma, distribution, and managed care. We’ll cover it all.

  • Timely Alerts

    We will provide key insights as soon as we learn- and it will not simply be forwarding a press release; we’ll provide relevant impact and insights. We want our clients informed to enable timely action.

“I’ve been working in the U.S. biosimilar market now for over fifteen years, and the available options for comprehensive, up to date information services on the U.S. biosimilars market are limited. I decided to leverage my industry experience and operational capacity to try and change that. With All Things Biosimilar, my goal is to establish the industry leading information platform to service the U.S. biosimilars market.”

Andrew Bourgoin

Principal, Bourgoin Insights Group, LLC and Founder of All Things Biosimilar

Ready to Subscribe to All Things Biosimilar? Contact us for pricing and to set up your subscription!